- Home
- KZIA vs TTNP Comparison
KZIA vs TTNP Comparison
Compare KZIA & TTNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- TTNP
- Stock Information
- Founded
- KZIA 1994
- TTNP 1991
- Country
- KZIA Australia
- TTNP United States
- Employees
- KZIA N/A
- TTNP N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KZIA Health Care
- TTNP Health Care
- Exchange
- KZIA Nasdaq
- TTNP Nasdaq
- Market Cap
- KZIA 5.1M
- TTNP 5.9M
- IPO Year
- KZIA 1999
- TTNP 1996
- Fundamental
- Price
- KZIA $10.45
- TTNP $4.37
- Analyst Decision
- KZIA Strong Buy
- TTNP
- Analyst Count
- KZIA 2
- TTNP 0
- Target Price
- KZIA $14.00
- TTNP N/A
- AVG Volume (30 Days)
- KZIA 745.7K
- TTNP 6.8K
- Earning Date
- KZIA 07-22-2025
- TTNP 08-14-2025
- Dividend Yield
- KZIA N/A
- TTNP N/A
- EPS Growth
- KZIA N/A
- TTNP N/A
- EPS
- KZIA N/A
- TTNP N/A
- Revenue
- KZIA $1,549,158.00
- TTNP N/A
- Revenue This Year
- KZIA N/A
- TTNP N/A
- Revenue Next Year
- KZIA N/A
- TTNP N/A
- P/E Ratio
- KZIA N/A
- TTNP N/A
- Revenue Growth
- KZIA 248983.08
- TTNP N/A
- 52 Week Low
- KZIA $2.86
- TTNP $3.03
- 52 Week High
- KZIA $79.00
- TTNP $14.80
- Technical
- Relative Strength Index (RSI)
- KZIA 72.75
- TTNP 48.42
- Support Level
- KZIA $5.86
- TTNP $4.12
- Resistance Level
- KZIA $7.20
- TTNP $4.65
- Average True Range (ATR)
- KZIA 1.17
- TTNP 0.19
- MACD
- KZIA 0.15
- TTNP -0.00
- Stochastic Oscillator
- KZIA 82.21
- TTNP 46.40
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.